샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744758

세계의 인테그라제 억제제 시장

Integrase Inhibitors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 371 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인테그라제 억제제 세계 시장은 2030년까지 192억 달러에 달할 전망

2024년에 151억 달러로 추정되는 인테그라제 억제제 세계 시장은 분석 기간 2024-2030년에 CAGR 4.1%로 성장하여 2030년에는 192억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 랄테그라비르은 CAGR 3.4%를 기록하며 분석 기간 종료시에는 63억 달러에 달할 것으로 예측됩니다. 돌루테그라비르 부문의 성장률은 분석 기간 동안 CAGR 4.0%로 추정됩니다.

미국 시장은 41억 달러로 추정, 중국은 CAGR 7.4%로 성장 예측

미국의 인테그라제 억제제 시장은 2024년에 41억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 39억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.7%와 3.1%로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예측됩니다.

세계의 인테그라제 억제제 시장 - 주요 동향과 촉진요인 정리

인테그라제 억제제가 HIV 및 신종 바이러스 감염 관리에 필수적인 이유는 무엇인가?

인테그라제 억제제는 레트로바이러스, 특히 인간면역결핍바이러스(HIV)의 복제에 중요한 효소인 인테그라제의 작용을 억제하도록 설계된 항레트로바이러스 약물의 한 종류입니다. 바이러스 DNA가 숙주 세포 유전체에 통합되는 것을 막음으로써 이 약물은 바이러스가 면역 세포에 감염되는 것을 막고 그 진행을 막습니다. 이러한 표적 메커니즘은 우수한 내약성과 최소한의 약물 상호 작용과 결합하여 전 세계 HIV 치료 요법의 첫 번째 선택 약물의 핵심이되었습니다.

이 약제는 주로 고활성 항레트로바이러스 요법(HAART)에 사용되어 바이러스 양을 억제하고, 면역 기능을 유지하며, HIV 감염의 위험을 감소시킵니다. 초기 항레트로바이러스제에 비해 작용 발현이 빠르고 내성에 대한 유전적 장벽이 높기 때문에 치료 경험이 없는 환자나 치료 경험이 있는 환자 모두에게 효과적이며, HIV 치료 전략이 보다 간편하고 내구성이 뛰어나며 내약성이 높은 요법으로 계속 진화하고 있는 가운데, 인테그라제 인테그라제 억제제는 최신 치료 프로토콜의 기본 요소로 자리 잡고 있습니다.

어떤 과학적 발전이 인테그라제 억제제 치료의 진화를 촉진하고 있는가?

퍼스트 인 클래스 약물이 도입된 이후, 인테그라제 억제제의 발전은 눈부신 발전을 이루었습니다. 차세대 화합물은 내성 프로파일을 개선하고, 독성을 낮추며, 더 쉽게 투여할 수 있도록 설계되었습니다. 랄테그라비르와 같은 초기 약물은 강력한 효능을 보였지만, 하루에 두 번 투여해야 했습니다. 이러한 한계는 돌테그라비르와 빅테그라비르와 같은 차세대 약물로 극복되었으며, 1일 1회 투여로 내성에 대한 장벽을 강화하여 복약 순응도를 높이고 장기적인 바이러스학적 억제를 가능하게 했습니다.

제형의 발전은 치료 패러다임을 더욱 재구성하고 있습니다. 인테그라제 억제제와 뉴클레오시드 역전사효소 억제제(NRTI) 병용요법은 정제의 부담을 줄이고 복용을 간소화하여 현재 일선 치료의 주류로 자리 잡았습니다. 카보테그라비르와 같은 지속형 주사제는 치료 수준을 장기간 유지하는 능력(월 1회부터 격월 주사까지)으로 주목받고 있으며, 환자의 경험과 순응도를 변화시키고 있습니다. 또한, 노출 전 예방약(PrEP) 및 기능적 치료 전략에 대한 사용도 연구되고 있습니다. 이러한 기술 혁신으로 인해 인테그라제 억제제의 유용성은 기존 치료 환경을 넘어 확장되고 있습니다.

인테그라제 억제제의 수요를 주도하는 치료 용도 및 환자군은?

인테그라제 억제제에 대한 수요의 주요 원동력은 전 세계 HIV 치료 및 예방 상황이며, 현재 주요 보건 당국이 일차 선택 약물로 권장하고 있습니다. 기존 요법에서 인테그라제 기반 병용요법으로의 전환은 고소득 국가에서 확산되고 있으며, 세계보건기구(WHO)의 노력과 제네릭 의약품의 가용성으로 인해 중저소득 지역에서도 확산되고 있습니다. 이러한 치료법은 새로 진단받은 성인과 소아부터 내성이 우려되는 오랜 치료 이력이 있는 환자까지 HIV 치료의 모든 단계에서 채택되고 있습니다.

소아 HIV 치료는 새로운 중점 분야로, 소아 친화적인 인테그라제 억제제 제제가 규제 당국의 승인을 받아 내약성이 우수한 치료제에 대한 접근성이 향상되고 있습니다. 또한, 약물-약물 상호작용 프로파일이 특히 중요한 임산부, 결핵 및 B형 간염 중복 감염자 등 특수 집단에 대한 연구도 진행되고 있습니다. 또한, PrEP 주사제 및 이식형 약물의 개발로 고위험군이지만 HIV 음성인 집단에서의 사용이 확대되고 있으며, 전 세계 HIV 예방 전략에서 이러한 약물의 역할이 강화되고 있습니다.

인테그라제 억제제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다...

인테그라제 억제제 시장의 성장은 항레트로바이러스 요법에 대한 세계 접근성 증가, 인테그라제 기반 요법으로의 임상적 전환, 지속형 제제에 초점을 맞춘 강력한 의약품 개발 파이프라인 등 여러 가지 요인에 의해 주도되고 있습니다. 새로운 인테그라제 억제제의 우수한 효능, 안전성 및 내성 프로파일은 선진국과 개발도상국의 의료 시스템 모두에서 선호되는 선택이 되고 있습니다. 조기 진단과 보편적 치료를 지지하는 공중보건 노력으로 인해 치료 대상이 되는 환자군이 확대되고 있습니다.

투여 방법, 특히 지속형 주사제 및 복합제의 지속적인 혁신은 환자들의 복약 순응도를 향상시키는 데 기여하고 있습니다. 제네릭 의약품 제조 및 세계 조달 프로그램은 특히 HIV 감염률이 높은 지역에서 의약품의 경제성과 접근성을 높이는 데 기여하고 있습니다. 또한, 박멸 전략과 기능성 치료제에서 인테그라제 억제제의 역할을 탐구하기 위해 진행 중인 임상시험은 새로운 시장 개척에 도움이 될 수 있습니다. 세계 HIV 대응이 성숙해지고 예방 전략이 탄력을 받으면서, 인테그라제 억제제는 진화하는 항바이러스 치료제의 전망에서 중요한 도구로 남을 것으로 보입니다.

부문

약제(랄테그라비르, 돌루테그라비르, 엘비테그라비르, 빅테그라비르, 기타 약제), 투여 경로(경구, 정맥내, 기타 투여 경로), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 32개사)

  • AbbVie Inc.
  • Aurobindo Pharma
  • Biocon Limited
  • Cipla Limited
  • Gilead Sciences Inc.
  • Hetero Labs Limited
  • Janssen Pharmaceuticals(Johnson & Johnson)
  • Laurus Labs
  • Merck & Co., Inc.
  • Micro Labs Ltd.
  • Mylan N.V.(now part of Viatris)
  • Mylan Pharmaceuticals
  • Novartis International AG
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Strides Pharma Science Limited
  • Viatris Inc.
  • ViiV Healthcare
  • Wockhardt Limited
  • Zydus Lifesciences

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.06.20

Global Integrase Inhibitors Market to Reach US$19.2 Billion by 2030

The global market for Integrase Inhibitors estimated at US$15.1 Billion in the year 2024, is expected to reach US$19.2 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Raltegravir, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Dolutegravir segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 7.4% CAGR

The Integrase Inhibitors market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Integrase Inhibitors Market - Key Trends & Drivers Summarized

Why Are Integrase Inhibitors Essential in the Management of HIV and Emerging Viral Infections?

Integrase inhibitors are a class of antiretroviral drugs designed to block the action of integrase-an enzyme critical for the replication of retroviruses, particularly human immunodeficiency virus (HIV). By preventing viral DNA from integrating into the host cell genome, these drugs stop the virus from establishing infection in immune cells, thus halting its progression. Their targeted mechanism, combined with favorable tolerability and minimal drug interactions, has made them the backbone of first-line HIV treatment regimens across the globe.

These agents are primarily used in highly active antiretroviral therapy (HAART) to suppress viral load, preserve immune function, and reduce the risk of HIV transmission. Compared to earlier antiretroviral classes, integrase inhibitors exhibit a rapid onset of action and high genetic barrier to resistance, making them effective in both treatment-naive and treatment-experienced patients. As HIV treatment strategies continue to evolve toward simplified, durable, and better-tolerated regimens, integrase inhibitors have become a foundational component of modern therapy protocols.

What Scientific Advancements Are Driving the Evolution of Integrase Inhibitor Therapies?

The integrase inhibitor landscape has advanced significantly since the introduction of the first-in-class drug. Newer-generation compounds have been engineered for improved resistance profiles, lower toxicity, and more convenient dosing. Early agents such as raltegravir demonstrated strong efficacy but required twice-daily administration. This limitation has been overcome by next-generation drugs such as dolutegravir and bictegravir, which offer once-daily dosing and enhanced barrier to resistance, supporting greater adherence and long-term virological suppression.

Formulation advancements are further reshaping treatment paradigms. Fixed-dose combinations of integrase inhibitors with nucleoside reverse transcriptase inhibitors (NRTIs) now dominate frontline therapy, reducing pill burden and simplifying administration. Long-acting injectable formulations, such as cabotegravir, are gaining attention for their ability to maintain therapeutic levels for extended periods-ranging from once-monthly to bi-monthly injections-transforming patient experience and adherence. Research is also underway to explore their use in pre-exposure prophylaxis (PrEP) and functional cure strategies. These innovations are expanding the utility of integrase inhibitors beyond traditional treatment settings.

Which Therapeutic Applications and Populations Are Driving Demand for Integrase Inhibitors?

The primary driver of integrase inhibitor demand is the global HIV treatment and prevention landscape, where these drugs are now recommended as first-line therapy by major health authorities. The transition from older regimens toward integrase-based combinations is widespread in high-income countries and is gaining ground in low- and middle-income regions due to global health initiatives and generic drug availability. These therapies are being adopted across all stages of HIV care-from newly diagnosed adults and children to heavily treated individuals with resistance concerns.

Pediatric HIV treatment is an emerging focus area, with child-friendly formulations of integrase inhibitors gaining regulatory approval and improving access to better-tolerated therapy. The drugs are also being studied in special populations such as pregnant women and individuals co-infected with tuberculosis or hepatitis B, where drug-drug interaction profiles are especially important. Additionally, the development of injectable and implantable integrase inhibitors for PrEP is expanding use among high-risk but HIV-negative populations, reinforcing the role of these drugs in global HIV prevention strategies.

The Growth in the Integrase Inhibitors Market Is Driven by Several Factors…

The growth in the integrase inhibitors market is driven by several factors including increasing global access to antiretroviral therapy, the clinical shift toward integrase-based regimens, and strong drug development pipelines focused on long-acting formulations. The superior efficacy, safety, and resistance profiles of newer integrase inhibitors are making them the preferred choice in both developed and developing healthcare systems. Public health initiatives advocating early diagnosis and universal treatment are expanding patient populations eligible for therapy.

Continued innovation in delivery methods-especially long-acting injectables and fixed-dose combinations-is supporting better patient adherence, which remains a cornerstone of successful HIV treatment outcomes. Generic manufacturing and global procurement programs are helping drive affordability and availability, particularly in regions with high HIV prevalence. Furthermore, ongoing clinical trials exploring the role of integrase inhibitors in eradication strategies and functional cures may open new market frontiers. As the global HIV response matures and prevention strategies gain momentum, integrase inhibitors are set to remain a critical tool in the evolving landscape of antiviral therapeutics.

SCOPE OF STUDY:

The report analyzes the Integrase Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Other Drugs); Administration Route (Oral, Intravenous, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Aurobindo Pharma
  • Biocon Limited
  • Cipla Limited
  • Gilead Sciences Inc.
  • Hetero Labs Limited
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Laurus Labs
  • Merck & Co., Inc.
  • Micro Labs Ltd.
  • Mylan N.V. (now part of Viatris)
  • Mylan Pharmaceuticals
  • Novartis International AG
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Strides Pharma Science Limited
  • Viatris Inc.
  • ViiV Healthcare
  • Wockhardt Limited
  • Zydus Lifesciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Integrase Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of HIV Infections Propels Long-Term Demand for Potent Antiretroviral Classes Like Integrase Inhibitors (INIs)
    • Shift Toward First-Line Regimens With Better Tolerability and Resistance Profiles Strengthens Adoption of Integrase Strand Transfer Inhibitors (INSTIs)
    • Introduction of Once-Daily Fixed-Dose Combinations Featuring INIs Enhances Patient Adherence and Simplifies HIV Treatment
    • Favorable Safety Profile and Rapid Viral Suppression Capability Position INSTIs as a Preferred Backbone in HIV Therapeutic Guidelines
    • Expansion of Long-Acting Injectable Regimens With INIs Drives Innovation in Extended-Release Formulations and Dual Therapies
    • Growth in HIV Pre-Exposure Prophylaxis (PrEP) Research Throws the Spotlight on INSTIs for Preventive Use in High-Risk Populations
    • Increasing Use of INSTIs in Pediatric and Adolescent HIV Treatment Expands Market Reach Across Age Groups
    • Rising Resistance to Older Classes Like NNRTIs and PIs Promotes Continued Uptake of INSTIs With High Genetic Barrier to Resistance
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Integrase Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Raltegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Raltegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Raltegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dolutegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Dolutegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Dolutegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Elvitegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Elvitegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Elvitegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bictegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Bictegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Bictegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Integrase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Integrase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Integrase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Integrase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제